Updated time: 2024-12-19 14:31:31
28A-1090304
US 11,918,641, B2 、US 11,992,525 B2、AU 2021268212、PCT、TW filing
Vaccination has been used to control the spread of influenza infection. We designed chimeric vaccines based on the most common avian influenza H5 and human influenza H1sequences. The chimeric hemagglutinin (cHA) vaccine with consensus H5 as globular head and consensus H1 as stem was the best and shown to elicit strong CD4+and CD8+ T-cell immune responses. The monoglycosylated cHA (cHAmg) vaccine with only GlcNAc on each glycosite induced more stem-specific antibodies, with higher antibody-dependent cellular cytotoxicity (ADCC), better neutralizing and stronger cross-protection activities against H1, H3, H5, and H7 strains and subtypes. Moreover, the cHAmg vaccine combined with a glycolipid adjuvant further enhanced the vaccine efficacy with more IFN-, IL-4 and CD8+ memory T cells produced.
- We designed chimeric vaccines based on the most common avian influenza H5 and human influenza H1 sequences.
- The chimeric hemagglutinin (cHA) vaccine with consensus H5 as globular head and consensus H1 as stem was the best and shown to elicit strong CD4+ and CD8+ T-cell immune responses.
- The monoglycosylated cHA (cHAmg) vaccine with only GlcNAc on wach glycosite induced more stem-specific antibodies, with higher antibody-dependent cellular cytotoxicity (ADCC), better neutralizing and stronger cross-protection activities against H1, H3, H5 and H7 strains and subtypes.
- The cHAmg vaccine combined with a glycolipid adjuvant further enhanced the vaccine efficacy with more IFN-γ, IL-4 and CD8+ memory T cells produced.
- Influenza vaccine
- Monoglycosylated chimeric hemagglutinin
- Monoglycosylated chimeric hemagglutinin together with glycolipid adjuvants

Fig1. The chimeric hemagglutinin (cHA) vaccine elicited strong immune responses

Fig2. The chimeric hemagglutinin (cHA) vaccine elicited broad neutralizing
Chi-Huey Wong, Hsin-Yu Lian, Shih-Chi Wang, Yi-An Ko, Kuo-I Lin, Che Ma, Ting-Jen Cheng
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

A designer chimeric hemagglutinin elicits broad-protective CD4 and CD8 T-cell responses